Thread by @rheum_cat

#ACR22 Spondyloarthritis posters

Abs 0382 McDermott, et al.

MGB study of new axSpA cohort (n=555) investigating dx delay

📌Dx delay in axSpA is well described:

https://twitter.com/rheum_cat/status/1318235472489971712?s=20&t=gZHYWeHT9uIHL5wR4ZbesA

#ACR22

Abs 0382 cont'd

Mean dx delay in this study: 6.8+/-8.5 yrs (consistent with prior studies)

In terms of factors a/w longer dx delay, they included the social vulnerability index, derived from US census data. This part is pretty novel

#ACR22

Abs 0382 cont'd

Higher SVI, uveitis a/w longer dx delay in axSpA

🤔Why might h/o uveitis be a/w a longer dx delay?

#ACR22

Abs 0388 @restovall

The first study of AS in the #RISE registry! 🥂
Years: 2016-2028
Medicare linkage ⛓
n=2092 AS

#ACR22

@restovall Abs 0388 cont'd

📌Increased fracture rate in AS is well established

https://twitter.com/rheum_cat/status/1520169321317687296?s=20&t=gZHYWeHT9uIHL5wR4ZbesA

#ACR22

@restovall Abs 0388 cont'd

What was a/w higher fx risk in multivariable models?
Age, BMI, comorbidities (similar to gen pop)
& chronic opioid use (OR 1.8)

👉Chronic opioid use: potentially intervenable RF for fx risk in AS

#ACR22

@restovall Abs 0389 @lihi_eder

💉Israel (Clalit) pop-based study on PsD COVID vax effectiveness
PsD matched to non-PsD comparators

🏥outcomes:
1) SARS-CoV2 infx
2) hospitalization 2/2 COVID

#ACR22

@restovall @lihi_eder Abs 0389 cont'd

👉VE: similar for PsD & comparators, both time periods (early & later vax eras)

👉When restricted to PsD to eval VE for diff meds, they saw that COVID vaccination was still effective, overall

Nice pop-level data from a country w a robust vax program

#ACR22

@restovall @lihi_eder Abs 0378 Deodhar et al
🔎CBP in chiropractic clinics: a referral strategy to eval for #axSpA

n=115 referred
n=65 seen by rheum
8/65 (12%) dx axSpA

#ACR22

@restovall @lihi_eder #0372 Ko, et al.

KOBIO (Korean biologic registry), 2012-2020
n=1610 AS
outcome: infx

In multivariable model: active disease (ASDAS-ESR>3.5) a/w higher infx risk
👉More support that active disease drives infx risk (cf. COVID)

#ACR22

@restovall @lihi_eder #0384 Shi, et al

single center (Hong Kong), 2001-2009
n=413 axSpA
💔outcome: incident HTN

In multivariable models, dz duration a/w higher HTN risk;
Looks like measures of inflammation only sig in univariable models

#ACR22

@restovall @lihi_eder #0329 Park, et al.
Korean study, n=185 axSpA

physical activity ➡function
adj for ASDAS, syndesmophyte #

(DAGs are hard to draw with emojis!)

#ACR22

@restovall @lihi_eder Abs 0329 cont'd

📌Always a good time to review the evidence behind exercise (and physical activity broadly) as an intervention for #axSpA

https://twitter.com/rheum_cat/status/1457784990326878215?s=20&t=7HwZOJsHM0FKbGUg2el9xQ

#ACR22